Dr. Yi Zhang is currently the Senior Advisor for oral drug products in Office of Generic Drugs. She received a Ph.D. in Pharmacology, Master of Medicines and Bachelor in Pharmaceutical Sciences. As a subject matter expert in developing and establishing optimal and rigorous bioequivalence (BE) standards and approaches for various drug dosage forms to promote generic drug development and approval, Dr. Zhang has pioneered, established and supervised the first-ever developed Product Specific Guidance (PSG) Program as the BE Director in Office of Bioequivalence, led multiple teams (topical, dermatological and oral) in Office of Research and Standards, and expedited global harmonization on generic drugs guidances. By publishing thousands of PSGs in guiding the industry for its generic drug development, responding to thousands of public inquires (including controlled correspondences and citizen petitions), managing hundreds of pre-ANDA meetings, addressing hundreds of internal consults, and leading bridging research projects to address broad regulatory scientific issues encountered throughout generic drug approvals, Dr. Zhang and her groups have improved FDA’s generic drug approval process, provided the transparent communication to the generic drug industry with regard to regulatory and scientific perspectives, facilitated the generic industry to develop generic drug products more efficiently and effectively by submitting high quality applications, and approved affordable medicines.
Dr. Yi Zhang is currently the Senior Advisor for oral drug products in Office of Generic Drugs. She received a Ph.D. in Pharmacology, Master of Medicines and Bachelor in Pharmaceutical Sciences. As a subject matter expert in developing and establishing optimal and rigorous bioequivalence (BE) standards and approaches for various drug dosage forms to promote generic drug development and approval, Dr. Zhang has pioneered, established and supervised the first-ever developed Product Specific Guidance (PSG) Program as the BE Director in Office of Bioequivalence, led multiple teams (topical, dermatological and oral) in Office of Research and Standards, and expedited global harmonization on generic drugs guidances. By publishing thousands of PSGs in guiding the industry for its generic drug development, responding to thousands of public inquires (including controlled correspondences and citizen petitions), managing hundreds of pre-ANDA meetings, addressing hundreds of internal consults, and leading bridging research projects to address broad regulatory scientific issues encountered throughout generic drug approvals, Dr. Zhang and her groups have improved FDA’s generic drug approval process, provided the transparent communication to the generic drug industry with regard to regulatory and scientific perspectives, facilitated the generic industry to develop generic drug products more efficiently and effectively by submitting high quality applications, and approved affordable medicines.